SCHEMBL286999

SCHEMBL286999

Cc1nc(C)c(C(=O)O)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 8/20 0.47
MAPT P10636 6/20 0.47
POLB P06746 5/20 0.47
USP2 O75604 4/20 0.47
TSHR P16473 4/20 0.47
HTT P42858 3/20 0.47
ALDH1A1 P00352 9/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 3/20 0.46
CYP1A2 P05177 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 2/20 0.40
NPC1 O15118 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10496189 0.98 HSD17B10 (0.46) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL20577473 0.87 HSD17B10 (0.40) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL27432878 0.85 HSD17B10 (0.47) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL210291 0.83 HSD17B10 (0.50) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL114334 0.81 MAPT (0.44) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL9297041 0.81 HSD17B10 (0.38) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL540823 0.81 ALDH1A1 (0.45) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL8615319 0.78 HSD17B10 (0.43) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL19770791 0.78 ALDH1A1 (0.41) HSD17B10MAPTPOLBUSP2TSHR
SCHEMBL8829451 0.78 ALDH1A1 (0.41) HSD17B10MAPTPOLBUSP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 294 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114478423-B Preparation method of 2, 4-dimethyl oxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2024-07-12 CN claimed
CN-114478423-A Preparation method of 2, 4-dimethyloxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2022-05-13 CN claimed
EP-2627637-B1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES HOFFMANN LA ROCHE (CH) 2016-06-29 EP claimed
EP-2627637-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2013-08-21 EP claimed
US-8461160-B2 Dihydropyrimidinones HOFFMANN-LA ROCHE, INC. (US) 2013-06-11 US claimed
WO-2012049190-A1 N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2012-04-19 WO claimed
CN-102083827-A Thiazolidine compounds as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD 2011-06-01 CN claimed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US claimed
WO-2010128058-A1 DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-11 WO claimed
US-20100286158-A1 DIHYDROPYRIMIDINONES HOFFMANN-LA ROCHE, INC. 2010-11-11 US claimed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO claimed
EP-4007758-B1 BIS-[N-((5-CARBAMOYL)-1H-BENZO[D]IMIDAZOL-2-YL)-PYRAZOL-5-CARBOXAMIDE] DERIVATIVES AND RELATED COMPOUNDS AS STING (STIMULATOR OF INTERFERON GENES) AGONISTS FOR THE TREATMENT OF CANCER MERSANA THERAPEUTICS INC (US) 2026-05-13 EP disclosed
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 US disclosed
EP-4143195-B1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 EP disclosed
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-02-20 US disclosed
US-5264448-A Thioamides, oxazole ring, insecticides, miticides SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-11-23 US disclosed
EP-0154132-B1 6-ALKYLIDENE PENEMS, THEIR PREPARATION AND USE, AND INTERMEDIATES BEECHAM GROUP PLC (GB) 1992-01-08 EP disclosed
EP-0394043-A1 An amide compound and its production and use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1990-10-24 EP disclosed
US-4798828-A LACTAMASE INHIBITORS BEECHAM GROUP P.L.C. (GB) 1989-01-17 US disclosed
EP-0154132-A1 6-Alkylidene penems, their preparation and use, and intermediates BEECHAM GROUP PLC (GB) 1985-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR HSD17B10 1862/4885MAPT 1096/4885POLB 4816/4885
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 HSD17B10 1040/4885MAPT 796/4885POLB 320/4885
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, ACAT1, ACAA2 HSD17B10 659/4885MAPT 1051/4885POLB 434/4885
US-20100286158-A1 DIHYDROPYRIMIDINONES BACE2, BACE1, PSEN2 HSD17B10 536/4885MAPT 143/4885POLB 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.